SPX-303

N/A

Report date: 2026/03/24 20:00:35
First In Class

Base Information

Drug NameSPX-303
Drug Alias NameSPX-303
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors +[4] 
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2Programmed death-ligand 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSparX Biopharmaceutical Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSparX Biopharmaceutical CorpKeba Biological (Jiangsu) Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A